SELLAS Life Sciences Group, Inc. (SLS)
2025-06-30 | ||||
|---|---|---|---|---|
| General and administrative | 3,002 | |||
| Research and development | 3,871 | |||
| Total operating expenses | 6,873 | |||
| Loss from operations | -6,873 | |||
| Interest income | 272 | |||
| Total non-operating income | 272 | |||
| Net loss | -6,601 | |||
| Net loss per common share, basic (in dollars per share) | -0.07 | |||
| Net loss per common share, diluted (in dollars per share) | -0.07 | |||
| Weighted-average common shares outstanding, basic (in shares) | 98,558,567 | |||
| Weighted-average common shares outstanding, diluted (in shares) | 98,558,567 | |||